COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher’s Stone?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher’s Stone?
Authors
Keywords
-
Journal
Diabetes Therapy
Volume 11, Issue 6, Pages 1195-1197
Publisher
Springer Science and Business Media LLC
Online
2020-05-07
DOI
10.1007/s13300-020-00830-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Diabetic Neuropathy Collection: Progress in Diagnosis and Screening
- (2020) Nikolaos Papanas Diabetes Therapy
- COVID-19 and diabetes: Can DPP4 inhibition play a role?
- (2020) Gianluca Iacobellis DIABETES RESEARCH AND CLINICAL PRACTICE
- Middle East respiratory syndrome
- (2020) Ziad A Memish et al. LANCET
- COVID-19 and Italy: what next?
- (2020) Andrea Remuzzi et al. LANCET
- COVID-19 and Diabetic Foot: Will the Lamp Burn Bright?
- (2020) Nikolaos Papanas et al. International Journal of Lower Extremity Wounds
- Hepatoprotective activity of metformin: A new mission for an old drug?
- (2019) Milad Iranshahy et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Pioglitazone ameliorates hepatic damage in irradiated rats via regulating anti-inflammatory and antifibrogenic signalling pathways
- (2019) Rasha R. Radwan et al. FREE RADICAL RESEARCH
- Therapies in non-alcoholic steatohepatitis (NASH)
- (2017) Abdul M. Oseini et al. LIVER INTERNATIONAL
- Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase
- (2017) Wei-Lun Tsai et al. Oncotarget
- Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis
- (2017) Pi-Jung Hsiao et al. Scientific Reports
- Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial
- (2016) Mary-Anne Doyle et al. Trials
- Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection
- (2015) Lindsay Matthews et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Metformin: a cheap and well-tolerated drug that provides benefits for viral infections
- (2012) J Joven et al. HIV MEDICINE
- Pioglitazone Decreases Hepatitis C Viral Load in Overweight, Treatment Naïve, Genotype 4 Infected-Patients: A Pilot Study
- (2012) Mario Chojkier et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started